The Stanniocalcin-PAPP-A-IGFBP-IGF Axis
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Claus Oxvig und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Aarhus University, DK-8000 C, Aarhus, Denmark. Hauptthemen laut MEDLINE: Pregnancy-Associated Plasma Protein-A, Insulin-Like Growth Factor I. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: Novo Nordisk Foundation.
Abstract (Originalsprache)
The pappalysin metalloproteinases, PAPP-A and PAPP-A2, have emerged as highly specific proteolytic enzymes involved in the regulation of insulin-like growth factor (IGF) signaling. The only known pappalysin substrates are a subset of the IGF binding proteins (IGFBPs), which bind IGF-I or IGF-II with high affinity to antagonize receptor binding. Thus, by cleaving IGFBPs, the pappalysins have the potential to increase IGF bioactivity and hence promote IGF signaling. This is relevant both in systemic and local IGF regulation, in normal and several pathophysiological conditions. Stanniocalcin-1 and -2 were recently found to be potent pappalysin inhibitors, thus comprising the missing components of a complete proteolytic system, the stanniocalcin-PAPP-A-IGFBP-IGF axis. Here, we provide the biological context necessary for understanding the properties of this molecular network, and we review biochemical data, animal experiments, clinical data, and genetic data supporting the physiological operation of this branch as an important part of the IGF system. However, although in vivo data clearly illustrate its power, it is a challenge to understand its subtle operation, for example, multiple equilibria and inhibitory kinetics may determine how, where, and when the IGF receptor is stimulated. In addition, literally all of the regulatory proteins have suspected or known activities that are not directly related to IGF signaling. How such activities may integrate with IGF signaling is also important to address in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Aarhus University, DK-8000 C, Aarhus, Denmark.
- Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Claus Oxvig, Cheryl A Conover
Förderung
- Novo Nordisk Foundation
Zitieren
APA
Oxvig, C., & Conover, C. A. (2023). The Stanniocalcin-PAPP-A-IGFBP-IGF Axis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad053
Vancouver
Oxvig C, Conover CA. The Stanniocalcin-PAPP-A-IGFBP-IGF Axis. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad053
BibTeX
@article{Oxvig2023,
author = {Oxvig, Claus and Conover, Cheryl A},
title = {The Stanniocalcin-PAPP-A-IGFBP-IGF Axis},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad053}
}
EUVIMED